Related Experiment Video
Updated: Jun 4, 2026
05:52
Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
Published on: June 30, 2011
Performance of a new reusable insulin pen
1Department of Endocrinology-Metabolism and Diabetology-Nutrition, University of Franche-Comté, Besançon, France. alfred.penfornis@univ-fcomte.fr
Diabetes Technology & Therapeutics
|February 5, 2011
Summary
The ClikSTAR insulin pen was found to be significantly easier to use by people with diabetes compared to other reusable pens. This improved ease of use, combined with strong performance, meets patient needs.
Area of Science:
- Diabetes management
- Medical device usability
- Pharmaceutical technology
Background:
- Multinational study comparing insulin pen usability.
- Focus on ClikSTAR vs. commonly used reusable pens.
- Involved participant and interviewer assessments.
Purpose of the Study:
- To compare the ease of use and performance of the ClikSTAR insulin pen.
- Evaluate ClikSTAR against Lilly Luxura and NovoPen 3 and 4.
- Assess usability based on patient and healthcare professional perspectives.
Main Methods:
- 654 people with diabetes demonstrated four insulin pens.
- Participants followed instruction manuals for each pen.
- Ease of use and task completion difficulty were primary endpoints.
Main Results:
- ClikSTAR was rated significantly easier to use, including by those with dexterity/visual impairments (P < 0.05).
- Participants using ClikSTAR experienced no difficulty completing tasks.
- Higher proportion of participants required no help with ClikSTAR (75%) compared to others.
Conclusions:
- ClikSTAR demonstrated superior ease of use compared to other insulin pens.
- The pen's overall performance meets the needs of people with diabetes.
- ClikSTAR offers a user-friendly option for insulin delivery.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...